Authors: Sona Michlikova1,2, Asier Rabasco Meneghetti1,2, Steffen Löck1,3,4, Artur Yakimovich5,6, Treewut Rassamegevanon1,3, Cläre von Neubeck1,3,7, Antje Dietrich1,3, Mechthild Krause1,2,3,4,8
1OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; 2Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany; 3German Cancer Consortium (DKTK), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, Germany; 4Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Department of Radiotherapy and Radiation Oncology, Dresden, Germany; 5Helmholtz-Zentrum Dresden - Rossendorf e.V. (HZDR), Center for Advanced Systems Understanding (CASUS), Görlitz, Germany; 6University College London, Royal Free Hospital Campus, Division of Medicine, Department of Renal Medicine, Bladder Infection and Immunity Group (BIIG), London, United Kingdom; 7University of Duisburg-Essen, Department of Particle Therapy, University Hospital Essen, Essen, Germany; 8National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany